(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 180.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.37%.
Absci's revenue in 2026 is $2,800,000.On average, 10 Wall Street analysts forecast ABSI's revenue for 2026 to be $1,353,779,114, with the lowest ABSI revenue forecast at $374,902,094, and the highest ABSI revenue forecast at $4,338,152,806. On average, 10 Wall Street analysts forecast ABSI's revenue for 2027 to be $5,673,722,390, with the lowest ABSI revenue forecast at $449,882,513, and the highest ABSI revenue forecast at $16,327,368,762.
In 2028, ABSI is forecast to generate $9,348,528,020 in revenue, with the lowest revenue forecast at $449,882,513 and the highest revenue forecast at $26,284,462,346.